Articles

P3.14 Effects of the immunomodulating peptide thymosin alpha 1 in multiple myeloma and immune reconstitution after hematopoietic stem cell transplantation in murine models

BJH - volume 6, issue Abstract Book BHS, january 2015

M. Binsfeld , M. Hannon , S. Humblet-Baron , Y. Beguin MD, PhD, prof. F. Baron , J. Caers MD, PhD

Read more

Vaccination guidelines in haematopoietic transplant patients: recommendations from the BHS Transplant Committee

BJH - volume 5, issue 2, june 2014

I. Moors MD, H. Schoemans MD, PhD, S. Callens MD, PhD, Y. Beguin MD, PhD, T. Kerre MD, PhD

Summary

Haematopoietic stem cell transplantation is increasingly used as consolidation therapy in severe haematological diseases. In the post-transplantation period, the immunity of haematopoietic stem cell transplantation recipients is impaired due to toxicity of the pre-haematopoietic stem cell transplantation treatment (chemo- and/or radiotherapy), the conditioning regimen with a reset of the immune system, and – in case of allogeneic haematopoietic stem cell transplantation – the use of immunosuppressive drugs and potentially graft-versus-host-disease. This leads to a considerably increased risk of infections, with high morbidity and mortality. Therefore, prevention of infections, i.a. by revaccination, is of major importance to improve outcomes. We present the Belgian guidelines for vaccination after haematopoietic stem cell transplantation, based on available data in the literature and international guidelines, taking into account the availability of vaccines and – if applicable – their reimbursement in Belgium. We describe a general vaccination schedule for post-haematopoietic stem cell transplantation patients, indications for pre-transplant vaccination and donor vaccination and an overview of special indications, such as travel vaccinations, vaccinations of close contacts and health care workers, with recommendations for titer follow-up.

(BELG J HEMATOL 2014;5(2):44–54)

Read more

P1.10 Immunomodulatory effects of Rapamycin in xenogeneic GVHD

BJH - volume 5, issue Abstract Book BHS, january 2014

G. Ehx , M. Hannon , S. Dubois , A. Halleux , L. Belle , P. Drion , Y. Beguin MD, PhD, S. Humblet-Baron , prof. F. Baron

Read more

O.2 Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation

BJH - volume 5, issue Abstract Book BHS, january 2014

M. Binsfeld , Y. Beguin MD, PhD, L. Belle , E. Otjacques , M. Hannon , A. Briquet PhD, P. Drion , B. Bogen , prof. F. Baron , J. Caers MD, PhD

Read more

O.3 Comparison of 2 nonmyeloablative regimens for allogeneic HCT: a phase II randomized study from the HCT committee of the BHS

BJH - volume 5, issue Abstract Book BHS, january 2014

prof. F. Baron , P. Zachée MD, PhD, J. Maertens MD, PhD, T. Kerre MD, PhD, A. Ory , L. Seidel , C. Graux MD, PhD, P. Lewalle MD, PhD, H. Schouten , K. Theunissen MD, R. Schots MD, PhD, Y. Beguin MD, PhD

Read more

O.6 Long-term survival in patients receiving rhEPO following allogeneic hematopoietic cell transplantation

BJH - volume 5, issue Abstract Book BHS, january 2014

A. Jaspers MD, PhD, prof. F. Baron , E. Willems MD, PhD, K. Hafraoui , C. Bonnet MD, Y. Beguin MD, PhD

Read more

P1.04 Multiple myeloma cells instruct myeloid-derived suppressor cells to release pro-angiogenic cytokines

BJH - volume 5, issue Abstract Book BHS, january 2014

M. Binsfeld , R. Heusschen PhD, V. Lamour , E. Van Valckenborgh PhD, A. Bellahcène , prof. F. Baron , Y. Beguin MD, PhD, J. Caers MD, PhD

Read more